top of page
  • Recruiting

NCT05243797: Phase 3: EMN 30 - Tec + Len Vs Len Alone NDMM as Maint. Therapy Post ASCT (MajesTEC-4)

Updated: Oct 24, 2022

EMN30 - MajesTEC-4

64007957MMY3003

MajesTEC-4 TECLISTAMAB MYELOMA TRIAL emn30

NCT05243797: Phase 3: Teclistamab + Lenalidomide Versus Lenalidomide Alone in NDMM Myeloma as Maintenance Therapy Post ASCT (MajesTEC-4)


A Study of Teclistamab in Combination With Lenalidomide Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4)

ClinicalTrials.gov Identifier: NCT05243797


This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.

 

Sponsor

European Myeloma Network


Collaborator

Janssen Pharmaceutical


Multiple Locations